Literature DB >> 33408096

Factors associated with syphilis seroprevalence in women with and at-risk for HIV infection in the Women's Interagency HIV Study (1994-2015).

Kristal J Aaron1, Ilene Brill2, Zenoria Causey-Pruitt3, Kerry Murphy4, Michael Augenbraun5, Seble Kassaye6, Joel E Milam7, Dominika Seidman8, Audrey L French9, Stephen J Gange10, Adaora A Adimora11, Anandi N Sheth12, Margaret A Fischl13, Barbara Van Der Pol3, Jeanne Marrazzo3, Mirjam-Colette Kempf3,2,14, Jodie Dionne-Odom3.   

Abstract

OBJECTIVE: Syphilis rates among women in the USA more than doubled between 2014 and 2018. We sought to identify correlates of syphilis among women enrolled in the Women's Interagency HIV Study (WIHS) to inform targeted interventions.
METHODS: The retrospective cross-sectional analysis of secondary data included women with HIV or at-risk of HIV who enrolled in the multisite US WIHS cohort between 1994 and 2015. Syphilis screening was performed at baseline. Infection was defined serologically by a positive rapid plasma reagin test with confirmatory treponemal antibodies. Sociodemographic and behavioural characteristics stratified by baseline syphilis status were compared for women enrolled during early (1994-2002) and recent (2011-2015) years. Multivariable binomial modelling with backward selection (p>0.2 for removal) was used to model correlates of syphilis.
RESULTS: The study included 3692 women in the early cohort and 1182 women in the recent cohort. Syphilis prevalence at enrolment was 7.5% and 3.7% in each cohort, respectively (p<0.01). In adjusted models for the early cohort, factors associated with syphilis included age, black race, low income, hepatitis C seropositivity, drug use, HIV infection and >100 lifetime sex partners (all p<0.05). In the recent cohort, age (adjusted prevalence OR (aPOR) 0.2, 95% CI 0.1 to 0.6 for 30-39 years; aPOR 0.5, 95% CI 0.2 to 1.0 for 40-49 years vs ≥50 years), hepatitis C seropositivity (aPOR 2.1, 95% CI 1.0 to 4.1) and problem alcohol use (aPOR 2.2, 95% CI 1.1 to 4.4) were associated with infection.
CONCLUSIONS: Syphilis screening is critical for women with HIV and at-risk of HIV. Targeted prevention efforts should focus on women with hepatitis C and problem alcohol use. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  HIV women; epidemiology; risk factors; seroprevalence; syphilis

Mesh:

Year:  2021        PMID: 33408096      PMCID: PMC9099234          DOI: 10.1136/sextrans-2020-054674

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   4.199


  30 in total

Review 1.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

2.  Trends in Selected Measures of Racial and Ethnic Disparities in Gonorrhea and Syphilis in the United States, 1981-2013.

Authors:  Harrell W Chesson; Chirag G Patel; Thomas L Gift; Sevgi O Aral
Journal:  Sex Transm Dis       Date:  2016-11       Impact factor: 2.830

3.  Characteristics of women reporting multiple recent sex partners presenting to a sexually transmitted disease clinic for care.

Authors:  Nicholas J Van Wagoner; Hanne Sybil Harbison; Jonathan Drewry; Elizabeth Turnipseed; Edward W Hook
Journal:  Sex Transm Dis       Date:  2011-03       Impact factor: 2.830

4.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

5.  Bacterial sexually transmitted infections among HIV-infected patients in the United States: estimates from the Medical Monitoring Project.

Authors:  Elaine W Flagg; Hillard S Weinstock; Emma L Frazier; Eduardo E Valverde; James D Heffelfinger; Jacek Skarbinski
Journal:  Sex Transm Dis       Date:  2015-04       Impact factor: 2.830

6.  Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living With Human Immunodeficiency Virus in the United States (2005-2016).

Authors:  Jodie Dionne-Odom; Andrew O Westfall; Julia C Dombrowski; Mari M Kitahata; Heidi M Crane; Michael J Mugavero; Richard D Moore; Maile Karris; Katerina Christopoulos; Elvin Geng; Kenneth H Mayer; Jeanne Marrazzo
Journal:  Clin Infect Dis       Date:  2020-12-03       Impact factor: 9.079

Review 7.  Screening for Syphilis Infection in Nonpregnant Adults and Adolescents: US Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; John W Epling; Francisco A R García; Matthew W Gillman; Diane M Harper; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; William R Phillips; Maureen G Phipps; Michael P Pignone
Journal:  JAMA       Date:  2016-06-07       Impact factor: 56.272

8.  A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy.

Authors:  Arlene C Seña; Xiao-Hui Zhang; Trudy Li; He-Ping Zheng; Bin Yang; Li-Gang Yang; Juan C Salazar; Myron S Cohen; M Anthony Moody; Justin D Radolf; Joseph D Tucker
Journal:  BMC Infect Dis       Date:  2015-10-28       Impact factor: 3.090

9.  Assessing process, content, and politics in developing the global health sector strategy on sexually transmitted infections 2016-2021: Implementation opportunities for policymakers.

Authors:  Andy Seale; Nathalie Broutet; Manjulaa Narasimhan
Journal:  PLoS Med       Date:  2017-06-27       Impact factor: 11.069

10.  Sexually Transmitted Infection Testing of HIV-Positive Medicare and Medicaid Enrollees Falls Short of Guidelines.

Authors:  Raphael J Landovitz; Jennifer L Gildner; Arleen A Leibowitz
Journal:  Sex Transm Dis       Date:  2018-01       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.